相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study
Yutaka Fujiwara et al.
INVESTIGATIONAL NEW DRUGS (2018)
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours
Noelia Nebot et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma
Tanner M. Johanns et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis
John J. Park et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma
Marine Rousset et al.
CLINICA CHIMICA ACTA (2017)
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Remy B. Verheijen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
Roelof W. F. van Leeuwen et al.
CLINICAL PHARMACOKINETICS (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Georgina V. Long et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Drug interaction between dabrafenib and immunosuppressive drugs: about one case
Matthieu Levavasseur et al.
MELANOMA RESEARCH (2016)
Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms
Diptee Kulkarni et al.
PHARMACOGENOMICS (2016)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors forMetastatic Melanoma
Giuliana Carlos et al.
JAMA DERMATOLOGY (2015)
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2015)
Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
V. L. M. Yip et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
Assessment of the Drug Interaction Potential and Single- and Repeat-Dose Pharmacokinetics of the BRAF Inhibitor Dabrafenib
A. Benjamin Suttle et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Gerald S. Falchook et al.
CLINICAL CANCER RESEARCH (2014)
Population Pharmacokinetics of Dabrafenib, a BRAF Inhibitor: Effect of Dose, Time, Covariates, and Relationship With Its Metabolites
Daniele Ouellet et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia
Suk-Kyun Yang et al.
NATURE GENETICS (2014)
Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases
Shruthi Vaidhyanathan et al.
DRUG METABOLISM AND DISPOSITION (2014)
The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk
Sarah K. Lawrence et al.
DRUG METABOLISM AND DISPOSITION (2014)
Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
Giusy Gentilcore et al.
BMC CANCER (2013)
RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation
Matthew Holderfield et al.
CANCER CELL (2013)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients With BRAF V600 Mutation-Positive Solid Tumors
Cathrine L. Denton et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Effects of Particle Size, Food, and Capsule Shell Composition on the Oral Bioavailability of Dabrafenib, a BRAF inhibitor, in Patients with BRAF Mutation-Positive Tumors
Daniele Ouellet et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Alexander M. Menzies et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
Alastair J. King et al.
PLOS ONE (2013)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
Tara R. Rheault et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases
Rajendar K. Mittapalli et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation
David A. Bershas et al.
DRUG METABOLISM AND DISPOSITION (2013)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases
Marie Cargnello et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Josette Carnahan et al.
MOLECULAR CANCER THERAPEUTICS (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
Zita Dubauskas et al.
CLINICAL GENITOURINARY CANCER (2009)
A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation
Sylvie Laquerre et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
